Research Paper Volume 15, Issue 11 pp 5032—5051
CLDN5 identified as a biomarker for metastasis and immune infiltration in gastric cancer via pan-cancer analysis
Figure 3. The relationship between CLDN5 expression and cancer patients' OS. (A) A forest plot of CLDN5 hazard ratios in 33 multiple cancers. (B) Kaplan-Meier survival curves of OS for patients groups defined by CLDN5 expression in GBM, KIRP, COADREAD, STAD, KIRC, LUSC, BLCA, MESO, UVM, PAAD, PCPG, and KICH.